Tag: provectus
October 6, 2016
Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders
Provectus Biopharmaceuticals a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it filed a registration statement on Form S-1... August 25, 2016
Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage oncology and dermatology biopharmaceutical company,... August 23, 2016
Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”) today announced... April 22, 2016
Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or “The Company”), announced... March 16, 2016
Provectus Amends Protocol for Phase 3 Study of PV-10
Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) announced that the protocol for its Phase 3 clinical trial for PV-10 as an investigational treatment... March 10, 2016
Provectus Biopharmaceuticals Changes Date of Quarterly Business Update Conference Call
Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT) today announce that it is changing the date for its fourth quarter and year-end conference call... March 1, 2016